Immunomic Therapeutics has operated a highly capital efficient business since its inception, augmenting investor capital with revenue from licensing and collaborative deals. The company has meet major milestones, most notably completing a first-in-human Phase I study of JRC-LAMP-vax. Additional important milestones are included below.
The Company has completed a Series A preferred offering which will support further clinical development of the Company’s promising programs.
ITI Files an IND for a Phase II Study for JRC2*-LAMP-Vax in Japan
ITI is Awarded an SBIR Grant for Multi Nut Allergy Immunotherapy
ITI Initiates a Phase IC Clinical Study
ITI Successfully Completes Phase IB Clinical Study
ITI completes $3M Bridge Round financing.
ITI successfully completes Phase IA for JRC-LAMP-Vax
“Chimeric Vaccines” patent, US Patent No. 8,318,173, issues in the US, company is provided IP protection until Apr 2022
ITI begins Phase IA clinical study of JRC-LAMP-Vax
ITI closes over-subscribed Series A Rights Offering round of funding at $2.9 million
ITI receives notice of EU patent allowance for “Chimeric Vaccines” patent, a core component of LAMP-Vax™ IP
ITI closes Series A round of funding for sale of $3M in common stock
ITI receives authorization from FDA to proceed with its Phase I clinical study for Japanese red cedar immunotherapeutic vaccine.
ITI enters into Collaborative Research and License Agreement with leading pharmaceutical company for applications in animal health, licenses several vaccines. The deal will bring several million dollars in fees and milestone payments.
Life Sciences Greenhouse, M.A.I.N. and Trisiras Capital close on funding with immediate and future funding options of $1.75 million
ITI selected as Frost & Sullivan Award Winner for 2010 Biotechnology Innovation of the Year Award in Vaccines
Geron announces GRNVAC1 results from AML study meet Phase I/II endpoints. 15 of 21 patients receiving therapy continue to be in remission, some for up to 3 years
ITI and Nature Technology agree to collaborate and cross-license vaccine technologies
Sub-license granted to Geron Corp. for development of LAMP-telomerase cancer vaccine. ITI receives upfront fee and milestone payments as well as royalties once commercialized
Exclusive, worldwide license to LAMP technology with Johns Hopkins University. ITI gains rights to all active LAMP-related Intellectual Property
Immunomic Therapeutics, Inc.
Headquarters: 1214 Research Blvd, Suite 2016, Hershey, PA 17036
Lab: 15010 Broschart Rd. Ste. 250, Rockville, MD 20850
© 2007-2013 Immunomic Therapeutics, Inc.
All rights reserved
|by: Design Media Land, LLC|